It was set up in 1983 and the company started off with merely 5 merchandises to bring around psychiatric unwellness. Sun Pharma is best known worldwide as the industry of forte Active Pharmaceuticals Ingredients and preparations.
However, the company is besides concerned with chronic interventions such as cardiology, psychopathology, neurology, gastroenterology, diabetology, and respiratory complaints. Active Pharmaceuticals Ingredients ( API ) include peptides, steroids, endocrines, and anti-cancer drugs and their quality is internationally approved. The international offices of Sun Pharmaceuticals Industries Ltd. are located in British Virgin Islands, Russia, and Bangladesh. In India, the offices are in Vapi, Silvassa, Panoli, Ahmednagar, and Chennai. Dilip S. Shanghvi is the Executive Chairmanaˆ¦The “ organized ” sector of India ‘s pharmaceutical industry consists of 250 to 300 companies, which account for 70 per centum of merchandises on the market, with the top 10 houses stand foring 30 per centum. However, the sum sector is estimated at about 20,000 concerns, some of which are highly little. Approximately 75 per centum of India ‘s demand for medical specialties is met by local fabrication
There are 3 major group companies of Sun Pharmaceuticals Industries are:
Caraco Pharmaceuticals Laboratories ( based in Detroit, Michigan )
Sun Pharmaceuticals Industries Inc. ( Michigan )
Sun Pharmaceuticals ( Bangladesh )
In 1983, when Sun Pharma was set up, it merely dealt with two metropoliss in India. West Bengal and Bihar. In 1985, it started merchandising nationally and by 2000, Sun Pharmaceuticals made its manner through the international market. Merchandises used in cardiology were manufactured in 1987 and at that clip, Monotrate was one of the first merchandises that was launched and went on to go a best-seller. In 1993, Sun Pharmaceuticals Industries set up their ain research institute and named it SPARC. SPARC became popular by bring forthing cognition and honing procedure development accomplishments across the universe. In 1994, Sun Pharma enrolled itself in the chief stock exchanges in India. Subsequently in 1995, the first API fabrication works was established at Panoli to tag its standard beyond competition and besides capture the international market.
Sun Pharmaceuticals shifted its central offices in Mumbai as it is at the centre of Indian commercial trade. The company began its first international acquisition with an sum of US $ 7.5 million, geting Caraco Pharm Lab in Detroit. After 8 acquisitions by 2000, Sun Pharma established another research centre at Mumbai with an aim to sharpen accomplishments for the US market. Subsequently on, the company introduced a few more intervention countries which include orthopaedicss, gynaecology, and oncology.
Sun Pharma ‘s speedy ascent is one of its best properties that has made it derive an international position across the universe. It is ever updated with the latest information and is extremely competent. Quality remains the premier concern and is maintained purely by the squad. There are 3 signifiers of medical specialties manufactured plied by the company: unwritten, injectable, and delivery-system based. Caraco Pharm and the Halol Pharm Lab have got the blessing of UKMHRA and USFDA in recent old ages.
Sun Pharmaceutical IndustriesA A Limited A
Regd Office: A Sun Pharma Advanced ResearchA Centre, Tandalja, Vadodara-390020 A
Corporate Office: Acme Plaza, Andheri-Kurla Road, Andheri ( E ) , Mumbai – 400059A
Consolidated Audited Financial Results for the Year ended March 31, 2010A
A
A
A
( Rs. in Lakhs ) A
A
A
Year EndedA
Year EndedA
A
A
31.03.10A
31.03.09A
A
A
AuditedA
AuditedA
IncomeA
A
A
Net Gross saless / Income from OperationsA
410,277A A
427,230A A
A
A
A
A
Entire IncomeA
410,277A A
427,230A A
ExpenditureA
A
A
( Increase ) in Stock-in-Trade and Work-in-ProgressA
A A A A A A A A A A A A A A A ( 3,244 ) A
A A A A A A A A A A A A A A A A A ( 9,373 ) A
Consumption of MaterialsA
A A A A A A A A A A A A A A 99,323 A A
A A A A A A A A A A A A A A A A A 89,368 A A
Purchase of Traded GoodsA
A A A A A A A A A A A A A A 13,704 A A
A A A A A A A A A A A A A A A A A A 5,693 A A
Employees’A CostA
A A A A A A A A A A A A A A 48,221 A A
A A A A A A A A A A A A A A A A A 43,986 A A
Depreciation / AmortisationA
A A A A A A A A A A A A A A 15,331 A A
A A A A A A A A A A A A A A A A A 12,329 A A
Other ExpenditureA
A A A A A A A A A A A A A 115,992 A A
A A A A A A A A A A A A A A A 111,168 A A
Entire ExpenditureA
289,327A A
253,171A A
Net income from Operations before Other Income, Interest & amp ; A TaxA
120,950A A
174,059A A
Other IncomeA
A A A A A A A A A A A A A A A A 9,145 A A
A A A A A A A A A A A A A A A A A A 8,684 A A
Net income before Interest & amp ; A TaxA
A A A A A A A A A A A A A 130,095 A A
A A A A A A A A A A A A A A A 182,743 A A
Net Interest IncomeA
A A A A A A A A A A A A A A 11,389 A A
A A A A A A A A A A A A A A A A A 12,174 A A
Net income after Interest but before TaxA
A A A A A A A A A A A A A 141,484 A A
A A A A A A A A A A A A A A A 194,917 A A
A A Tax Expense A
A A A A A A A A A A A A A A A A 6,786 A A
A A A A A A A A A A A A A A A A A A 7,116 A A
Net Net income from Ordinary Activities after Tax before Minority InterestA
A A A A A A A A A A A A A 134,698 A A
A A A A A A A A A A A A A A A 187,801 A A
A A Minority InterestA A A
A A A A A A A A A A A A A A A A A A ( 410 ) A
A A A A A A A A A A A A A A A A A A 6,028 A A
Net Net income after Minority InterestA
A A A A A A A A A A A A A 135,108 A A
A A A A A A A A A A A A A A A 181,773 A A
Paid-up Equity Share CapitalA
A
A
Equity Shares – Face Value Rs. 5/- eachA
A A A A A A A A A A A A A A 10,356 A A
A A A A A A A A A A A A A A A A A 10,356 A A
Militias excepting Revaluation ReserveA
A A A A A ( As per last Audited Balance Sheet ) A
A A A A A A A A A A A A A 772,535 A A
A A A A A A A A A A A A A A A 694,136 A A
A Gaining Per Share – Roentgen. ( Basic & A ; A Diluted ) A A A
65.2A A
87.8A A
A
A
A
A
Public ShareholdingA
A
A
No. of Equity Shares of Rs. 5/- eachA
A A A A A A A A 75,150,451 A A
A A A A A A A A A A 75,154,439 A A
A
Percentage of ShareholdingA
36.28A A
36.29A A
Promoters and Promoter Group ShareholdingA
A
A
a ) A
Pledged / EncumberedA
A
A
A
No. of Equity Shares of Rs. 5/- eachA
A A A A A A A A A A A A A 685,000 A A
A A A A A A A A A A A A A A A 785,500 A A
A
Percentage of Equity Shares ( as a % of the entire portion keeping of promotersA and booster group ) A
0.52A A
0.60A A
A
Percentage of Equity Shares ( as a % of the entire portion capital of the Company ) A
0.33A A
0.38A A
B ) A
Non-encumberedA
A
A
A
No. of Equity Shares of Rs. 5/- eachA
A A A A A A 131,280,940 A A
A A A A A A A A 131,176,452 A A
A
Percentage of Equity Shares ( as a % of the entire shareholding of boosters and booster group ) A
99.48A A
99.40A A
A
Percentage of Equity Shares ( as a % of the entire portion capital of the Company ) A
63.39A A
63.33A A
Research & A ; A Development Expenses incurredA
A A A A A A A A A A A A A A 24,722 A A
A A A A A A A A A A A A A A A A A 31,
Sun Pharmaceutical IndustriesA A Limited A
Regd Office: A Sun Pharma Advanced ResearchA Centre, Tandalja, Vadodara-390020 A
Corporate Office: Acme Plaza, Andheri-Kurla Road, Andheri ( E ) , Mumbai – 400059A
Consolidated Audited Financial Results for the Year ended March 31, 2010A
A
A
A
( Rs. in Lakhs ) A
A
A
Year EndedA
Year EndedA
A
A
31.03.10A
31.03.09A
A
A
AuditedA
AuditedA
IncomeA
A
A
Net Gross saless / Income from OperationsA
410,277A A
427,230A A
A
A
A
A
Entire IncomeA
410,277A A
427,230A A
ExpenditureA
A
A
( Increase ) in Stock-in-Trade and Work-in-ProgressA
A A A A A A A A A A A A A A A ( 3,244 ) A
A A A A A A A A A A A A A A A A A ( 9,373 ) A
Consumption of MaterialsA
A A A A A A A A A A A A A A 99,323 A A
A A A A A A A A A A A A A A A A A 89,368 A A
Purchase of Traded GoodsA
A A A A A A A A A A A A A A 13,704 A A
A A A A A A A A A A A A A A A A A A 5,693 A A
Employees’A CostA
A A A A A A A A A A A A A A 48,221 A A
A A A A A A A A A A A A A A A A A 43,986 A A
Depreciation / AmortisationA
A A A A A A A A A A A A A A 15,331 A A
A A A A A A A A A A A A A A A A A 12,329 A A
Other ExpenditureA
A A A A A A A A A A A A A 115,992 A A
A A A A A A A A A A A A A A A 111,168 A A
Entire ExpenditureA
289,327A A
253,171A A
Net income from Operations before Other Income, Interest & amp ; A TaxA
120,950A A
174,059A A
Other IncomeA
A A A A A A A A A A A A A A A A 9,145 A A
A A A A A A A A A A A A A A A A A A 8,684 A A
Net income before Interest & amp ; A TaxA
A A A A A A A A A A A A A 130,095 A A
A A A A A A A A A A A A A A A 182,743 A A
Net Interest IncomeA
A A A A A A A A A A A A A A 11,389 A A
A A A A A A A A A A A A A A A A A 12,174 A A
Net income after Interest but before TaxA
A A A A A A A A A A A A A 141,484 A A
A A A A A A A A A A A A A A A 194,917 A A
A A Tax Expense A
A A A A A A A A A A A A A A A A 6,786 A A
A A A A A A A A A A A A A A A A A A 7,116 A A
Net Net income from Ordinary Activities after Tax before Minority InterestA
A A A A A A A A A A A A A 134,698 A A
A A A A A A A A A A A A A A A 187,801 A A
A A Minority InterestA A A
A A A A A A A A A A A A A A A A A A ( 410 ) A
A A A A A A A A A A A A A A A A A A 6,028 A A
Net Net income after Minority InterestA
A A A A A A A A A A A A A 135,108 A A
A A A A A A A A A A A A A A A 181,773 A A
Paid-up Equity Share CapitalA
A
A
Equity Shares – Face Value Rs. 5/- eachA
A A A A A A A A A A A A A A 10,356 A A
A A A A A A A A A A A A A A A A A 10,356 A A
Militias excepting Revaluation ReserveA
A A A A A ( As per last Audited Balance Sheet ) A
A A A A A A A A A A A A A 772,535 A A
A A A A A A A A A A A A A A A 694,136 A A
A Gaining Per Share – Roentgen. ( Basic & A ; A Diluted ) A A A
65.2A A
87.8A A
A
A
A
A
Public ShareholdingA
A
A
No. of Equity Shares of Rs. 5/- eachA
A A A A A A A A 75,150,451 A A
A A A A A A A A A A 75,154,439 A A
A
Percentage of ShareholdingA
36.28A A
36.29A A
Promoters and Promoter Group ShareholdingA
A
A
a ) A
Pledged / EncumberedA
A
A
A
No. of Equity Shares of Rs. 5/- eachA
A A A A A A A A A A A A A 685,000 A A
A A A A A A A A A A A A A A A 785,500 A A
A
Percentage of Equity Shares ( as a % of the entire portion keeping of promotersA and booster group ) A
0.52A A
0.60A A
A
Percentage of Equity Shares ( as a % of the entire portion capital of the Company ) A
0.33A A
0.38A A
B ) A
Non-encumberedA
A
A
A
No. of Equity Shares of Rs. 5/- eachA
A A A A A A 131,280,940 A A
A A A A A A A A 131,176,452 A A
A
Percentage of Equity Shares ( as a % of the entire shareholding of boosters and booster group ) A
99.48A A
99.40A A
A
Percentage of Equity Shares ( as a % of the entire portion capital of the Company ) A
63.39A A
63.33A A
Research & A ; A Development Expenses incurredA
A A A A A A A A A A A A A A 24,722 A A
A A A A A A A A A A A A A A A A A 31,
ANNUAL REPORTS OF THE COMPANY SUN PHARMA FOR PAST 3 Old age: –
Fiscal Statements 2007-08-09
In conformity with Clause 49 of the Listing Agreement with Stock Exchanges, the Company submits the study on the affairs
mentioned in the said Clause and lists the patterns followed by the Company.
1. Company ‘s Doctrine on Corporate Administration
The Company ‘s doctrine on Corporate Governance is guided by strong accent on transparence, answerability, duty, equity, unity, consistent value systems, and deputation across all aspects of its operations taking to aggressively focussed and operationally efficient growing. The Company ‘s beliefs on Corporate Governance are intended at back uping the direction of the Company for competent behavior of its concern and guaranting long term value for stockholders, every bit good as clients, providers, employees and statutory governments. The Company is committed to implement the criterions of good Corporate Governance and enterprises to continue and foster these nucleus values in all its activities with an purpose to increase and prolong its corporate value through growing and
invention.
2. Board of Directors
The present strength of the Board of Directors of your Company is six Directors.
Composition and class of Directors is as follows:
Category Name of the Director Inter-se Relationship
between Director
Promoter Executive Director Mr. Dilip S. Shanghvi Brother-in-law of
( Chairman and Managing Director ) Mr. Sudhir V. Valia
Non-Promoter Executive Director Dr. T. Rajamannar –
( Whole – Time Director )
Non Executive & A ; Mr. Sudhir V. Valia Brother-in-law of
Non Independent Director Mr. Dilip S. Shanghvi
Mr. S. Mohanchand Dadha –
Non Executive Independent Directors Dr. Goverdhan Mehta –
Dr. Andrea Vasella –
Number of Board Meetings held and the day of the months on which held: 8 Board meetings were held during the twelvemonth, as against
the minimal demand of 4 meetings.
Brief information on Directors proposed for reappointment:
The brief sketch, experience and other inside informations of the Directors, viz. Dr. T. Rajamannar and Mr. S. Mohanchand Dadha who retire by rotary motion at the resulting Annual General Meeting, and are proposed to be reappointed is given as under:
( a ) Dr. T. Rajamannar ( 46 old ages ) , is a M. Sc. from University of Madras, Ph.D in Organic Chemistry from IIT Madras and holds Post Doctoral making from University of Zurich, Switzerland. He has extended experience in the pharmaceutical Industry.
Dr. T. Rajamannar was an employee of Sun Pharmaceutical Industries Ltd. , since 1993 and has been transferred to SPARC pursuant to the Scheme of Arrangement for Demerger sanctioned by the Honourable High Court of Gujarat at Ahmedabad, and at present he is the Whole-Time Director of the Company. He has 15 research publications in international diaries and over 100 patent applications filed, to his recognition.
3. Code of Conduct
The Board of Directors have laid down a codification of behavior for all Board members and senior direction of T Company. All the Directors and senior direction forces have affirmed conformity with the codification of behavior as sanctioned and adopted by the Board of Directors and a declaration to this consequence has been annexed to the Corporate Governance Report. The codification of behavior has been posted on the web site of the Company www.sunpharma.in.
4. Audit Committee
The Board of the Company, has constituted an Audit commission with consequence from 4th June, 2007, which comprises of three independent non-executive Directors viz. Mr. S. Mohanchand Dadha, Dr. Goverdhan Mehta and Dr. Andrea Vasella. Mr. S. Mohanchand Dadha is the Chairman of the Audit Committee. The fundamental law of Audit Committee besides meets with the demands under Section 292A of the Companies Act, 1956. Mr. Sunil R. Ajmera the Company Secretary of the Company is the Secretary of the Audit Committee.
The Audit Committee is responsible for supervising the Company ‘s fiscal coverage procedure, reexamining the quarterly/ half yearly/ one-year fiscal statements, reexamining with the direction the fiscal statements and adequateness of internal audit map, urging the appointment/ re-appointment of statutory hearers and arrested development of audit fees, ,reviewing the important internal audit findings/ related party minutess, reexamining the Management Discussion and Analysis of fiscal status and consequence of operations and besides statutory conformity issues. The Committee acts as a nexus between the direction, external and internal hearers and the Board of Directors of the Company. Executives from the Finance Department, Representatives of the Statutory Auditors and Internal Hearers are besides invited to go to the Audit Committee Meetings.
:
Name of the Director Chairman/Member No. of Audit Committee
Meetings attendence
Mr. S. Mohanchand Dadha Chairman 4
Dr. Goverdhan Mehta Member 4
Dr. Andrea Vasella Member 4
5. Remuneration Committee
The Company has formed a Remuneration Committee of its Board of Directors with consequence from 23rd July, 2007. The Committee comprises of three non-executive and independent Directors Mr. S. Mohanchand Dadha, Dr. Goverdhan Mehta and Dr. Andrea Vasella as Members of the Committee. Mr. S. Mohanchand Dadha is the Chairman of the Committee.
6. Shareholders’/Investors ‘ Grievance Committee
The Board of the Company had constituted a Shareholders’/Investors ‘ Grievance Committee with consequence from 4th June, 2007, consisting of Mr. Dilip S. Shanghvi, Dr. T. Rajamannar, Mr. S. Mohanchand Dadha as members with Mr. Sudhir V. Valia as the Chairman of the Committee. However, at the Board Meeting held on 5th September, 2007, Mr. S. Mohanchand Dadha and Mr. Dilip S. Shanghvi indicated their inability to go on as members of Shareholders/ Investors Grievance Committee, due to their other pre-occupations hence resigned as members of the Committee. The Board of Directors hence reconstituted the said Committee and soon the commission comprises of Dr. T. Rajamannar, Dr. Goverdhan Mehta, Prof. Dr. Andrea Vasella as members with Mr. Sudhir V. Valia, Non-Executive Director, as the Chairman of the Committee.
The Committee, inter alia, approves issue of duplicate certifications and oversees and reexamine all affairs connected with the transportation of securities. The Committee looks into stockholders ‘ ailments like transportation of portions, non reception of balance sheet, non reception of declared dividends, etc. The Committee oversees the public presentation of the Registrar and Transfer Agents, and recommends steps for overall betterment in the quality of investor services. The Board of Directors has delegated the power of O.K.ing transportation of securities to M/s. Intime Spectrum Registry Ltd, and/or the Company Secretary of the Company.
7. Committee of Directors ( Allotment ) /Share Allotment Committee
Pursuant to clause 10.2 of the Scheme of Arrangement for Demerger sanctioned by the Honourable High Court of
Gujarat vide its order dated 01.03.2007 issued on 28.03.2007, wherein the Innovative Research & A ; Development Unit stands vested in the Company, and as per the Supplementary Trust Deed dated 18.05.2007, entered into by the Company with Sun Pharmaceutical Industries Ltd. and Citicorp Trustee Co. Ltd. , the Foreign Currency Convertible Bond.
8. Auxiliary Companies
The Company does non hold any subordinate.
42
9. General Body Meetings
( I ) Location and clip of the Annual General Meetings ( AGM ) held during the last 3 old ages, are as follows:
Year Meeting Location Date Time
2005-06 First AGM SPARC, Tandalja, Vadodara – 390 020 Gujarat 12-08-2006 10.30 A.M
2006-07 Second AGM Chandarva Hall, Welcom Hotel, 05-09-2007 11.45 A.M
R. C. Dutt Road, Vadodara – 390 007 Gujarat
( two ) Particular Resolutions passed during the last three old ages
( a ) At the First Annual General Meeting:
1. Authority for Inter Corporate Loans and Investment under Section 372A of the Companies Act, 1956, upto the
bounds specified in the declaration.
2. Authority to the Board to borrow in surplus of the aggregative Paid-up Capital and its Free Militias pursuant to
subdivision 293 ( 1 ) ( vitamin D ) of the Companies Act, 1956, upto the bounds specified in the declaration.
3. Authority to the Board pursuant to subdivision 293 ( 1 ) ( a ) of the Companies Act, 1956, upto the bounds specified in the declaration.
4. Authority to the Board pursuant to subdivision 293 ( 1 ) ( vitamin E ) of the Companies Act, 1956, upto the bounds specified in the declaration.
NOTICE OF ANNUAL GENERAL Meeting
The Dividend on Equity and Preference portions of the Company as declared by the Company will be paid on or after 3rd October, 2003, to the Company ‘s Equity and Preference stockholders whose names stand registered on the Company ‘s Register of Members as Beneficial Owners as at gap of concern as on 26th September, 2003 as per the list provided by National Securities Depository Limited and Central Depositories Services Limited in regard of the portions held in electronic signifier and as Members in the registry of Members of the Company after giving consequence to valid transportations in physical signifier lodged with the Company before 26th September, 2003.
4. At the Extra Ordinary General Meeting of the members of the Company held on Monday,1st September, 2003, the Members have approved, by manner of Particular Resolution, certain amendments to the Articles of Association of the Company associating to enabling the Company to implement any direction from a Member ( s ) of the Company to waive/forgo his/their right to have the dividend ( interim or concluding ) from the Company for any fiscal twelvemonth. Thus the Members of the Company can now waive/forgo, if he/they so desire ( s ) , his/their right to have the dividend ( interim or concluding ) for any fiscal twelvemonth effectual from the dividend recommended by the Board of Directors of the Company for the twelvemonth ended 31st March, 2003 on a twelvemonth to twelvemonth footing, as per the regulations framed by the Board of Directors of the Company from clip to clip for this intent. The Shareholder, if so wishes to relinquish /forgo the right to have Dividend for the twelvemonth ended 31st March, 2003 shall make full up the signifier and direct it to the Company ‘s Registrars on or before 26th September, 2003.The signifier prescribed by the Board of Directors of the Company for waiving/forgoing the right to have
THE BOARD OF DIRECTORS OF THE COMPANY AT ITS MEETING HELD ON 1ST
SEPTEMBER, 2003 HAVE FRAMED THE FOLLOWING RULES UNDER ARTICLE 190 A OF THE ARTICLES OF ASSOCIATION OF THE COMPANY FOR EQUITY SHAREHOLDERS WHO WANT TO WAIVE/FORGO THE RIGHT TO RECEIVE DIVIDEND IN RESPECT OF FINANCIAL YEAR 2007-2008 OR FOR ANY YEAR THEREAFTER.
I A Stockholder can waive/forgo the right to have the dividend ( either concluding and/or meantime ) to which he is entitled, on some or all the Equity Shares held by him in the Company as on the Record Date/Book Closure Date fixed for finding the names of Members entitled for such dividend. However, the stockholders can non waive/forgo the right to have the dividend ( either concluding and/or meantime ) for a portion of per centum of dividend on portion ( s ) .
II The Equity Shareholder ( s ) who wish to waive/forgo the right to have the dividend for any twelvemonth shall inform the Company in the signifier prescribed by the Board of Directors of the Company merely.
III In instance of joint holders keeping the Equity Shares of the Company, all the joint holders are required to adumbrate to the Company in the prescribed form their determination of waiving/forgoing their right to have the dividend from the Company.
IV The Shareholder, who wishes to waive/forgo the right to have the dividend for any twelvemonth shall direct his irrevokable direction waiving/forgoing dividend so as to make the Company before the Record Date /Book Closure Date fixed for the payment of such dividend. Under no fortunes, any direction received for waiver/forgoing of the right to have the dividend for any twelvemonth after the Record Date /Book Closure Date fixed for the payment of such dividend for that twelvemonth shall be given consequence to.
V The direction one time given by a Shareholder adumbrating his waiver/forgoing of the right to have the
dividend for any twelvemonth for meantime, concluding or both shall be irrevokable and can non be withdrawn for that
peculiar twelvemonth for such waived/forgone the right to have the dividend. But in instance, the relevant Shares are sold by the same Shareholder before the Record Date/Book Closure Date fixed for the payment of such dividend, the direction one time exercised by such earlier Shareholder adumbrating his waiver/forgoing the right to have dividend will be invalid for the following succeeding Shareholder ( s ) unless such following wining Shareholder ( s ) intimates individually in the prescribed signifier, about his waiving/forgoing of the right to have the dividend for the peculiar twelvemonth
10. Disclosures
a?¦ No dealing of a material nature has been entered into by the Company with Directors or Management and their relations, etc. that may hold a possible struggle with the involvements of the Company. The Register of contracts incorporating minutess, in which managers are interested, is placed before the Board of Directors on a regular basis. The dealing with the related parties are disclosed in the Annexure A attached to the Annual Histories.
a?¦ There were no cases of non-compliance by the Company on any affairs related to the capital markets or penalties/ stenosiss imposed on the Company by the Stock Exchange or SEBI or any statutory authorization during the last three fiscal old ages.
a?¦ In the readying of the fiscal statements, the Company has followed the Accounting Standards as notified by Companies ( Accounting Standard ) Rules, 2006.
a?¦ The Company has laid down processs to inform Board members about the hazard appraisal and its minimisation, which are sporadically reviewed to guarantee that hazard control is exercised by the direction efficaciously.
a?¦ During the twelvemonth under reappraisal, the Company has non raised financess through any public, rights or discriminatory issue.
a?¦ Adoption/ Non Adoption of the Non- mandatary demands:
( I ) The Company has non fixed a period of nine old ages as the term of office of Independent Directors on the Board of the
Company.
11. Means of Communication
a?¦ Website: The Company ‘s website www.sunpharma.in contains a separate dedicated subdivision ‘Financials ‘ where
stockholders information is available. Full Annual Report is besides available on the web site in a user friendly and
downloadable signifier. Apart from this, official intelligence releases, elaborate presentations made to media, analysts etc. are besides displayed on the Company ‘s web site.
a?¦ Financial Results: The one-year, semiannual and quarterly consequences are on a regular basis posted by the Company on its website www.sunpharma.in. These are besides submitted to the Stock Exchanges in conformity with the Listing Agreement and published in all English Editions and Gujarati Edition of ‘Financial Express ‘ .
a?¦ Annual Report: Annual Report incorporating inter alia Audited Annual Accounts, Directors ‘ Report, Auditors ‘ Report, and other of import information is circulated to Members and others entitled thereto. The Management ‘s Discussion and Analysis ( MD & A ; A ) Report forms portion of the Annual Report.
a?¦ Corporate filing: Announcements, Quarterly Results, Shareholding Pattern etc. of the Company on a regular basis filed by the Company, are besides available on the web site of The Bombay Stock Exchange Ltd. – www.bseindia.co.in, National Stock Exchange of India Ltd. – www.nseindia.co.in, and Corporate Filing & A ; Dissemination System website – www.corpfiling.co.in.
12. General Shareholder Information
12.1 Annual General Meeting:
– Date and Time: Saturday, 6th September, 2008
at 11.15 am.
– Venue: Hotel Taj Residency, Akota Gardens, Akota,
Vadodara – 390 020, Gujarat.
12.2 Financial Calendar ( probationary ) : Consequences for one-fourth stoping 30th June
2008 – Last hebdomad of July 2008.
: Consequences for one-fourth stoping 30th September
2008 – Last hebdomad of October 2008.
: Consequences for one-fourth stoping 31st December
2008 – Last hebdomad of January 2009.
: Audited Consequences for twelvemonth ended 31st March
2009 – 3rd or 4th hebdomad of May 2009.
12.3 Detailss of Book Closure For Equity Shareholders: From Wednesday, 27th August, 2008 to Saturday,
6th September, 2008 ( both yearss inclusive ) .
12.4 Dividend Payment Date: N.A.
12.5 ( I ) List of Equity Shares on Stock Exchanges: The Equity Shares of the Company have been listed during
the twelvemonth, at The Bombay Stock Exchange Ltd. , ( BSE ) and The
National Stock Exchange of India Ltd. ( NSE ) , with consequence from
18th July, 2007.
( two ) Payment of Listing Fee: List Fees for the twelvemonth ended 2008-09 have been paid to
The Bombay Stock Exchange Ltd. , and The National Stock
Exchange of India Ltd, where the Company ‘s Equity Shares
continue to be listed.
44
12.6 Stock Code:
Equity Shares
( a ) Trading Symbol The Bombay Stock Exchange Ltd. , ( Demat Segment ) : SUNPHA ADV 532872
Trading Symbol National Stock Exchange ( Demat Segment ) : SPARC
( B ) Demat ISIN Numbers in NSDL and CDSL for Equity Shares of Re.1/- each ISIN No. INE232I01014
Corporate Social Responsibility ( CSR )
Your organisation has identified wellness, instruction, catastrophe alleviation and sporadically, patient consciousness as countries of precedence. Our accent is assistance on a need footing and sooner at a local degree, working with a local organic structure, NGO or bing organisation. One individual ‘s instruction can do a difference to an full household. Your organisation continues to back up tribal instruction, at small town schools called ashram pathshalas across several provinces. We have frequently stepped in to back up substructure in the small town schools around our workss and offices. We helped Adarsh Kanyashala, near our R & A ; D centre in Baroda, with computing machine installations. In
Ahmednagar, support is extended to Gramin Vikas Mandal, which runs a primary school in the MIDC country, for kids whose parents are employed in the industrial country. We have helped the school direction in the high school in Karkhadi with fiscal aid for scientific discipline carnival, school twenty-four hours, etc. A nomadic new wave undertaking has been sponsored for instruction in the rural and tribal countries near Panoli and this is organized by Ankleshwar Industrial Development Society. Another of import activity was aid at the primary and university degrees, including support to pupils of the MS University of Baroda. Last twelvemonth, we donated a 150-seater inn for the station alumnus pupils of SSG Medical College, MS University. For old ages now, we have been assisting pupils work towards their doctor’s degrees utilizing the installations at SPARC. Your company on a regular basis patrons symposia, laboratory equipments and some production machines for local colleges. Amongst of import medical support activities was the contribution of machines and medical specialties to general infirmary near our workss. For case, the Panoli works gave fiscal aid to Smt. Jayaben Modi Hospital for its rural and tribal medical medical examination plans.
In Bangladesh last twelvemonth, we helped a group of head-shrinkers with the development of an IQ evaluation graduated table. We besides assisted wellness medical examination cantonments in distant rural countries. We donated a calorimeter to a infirmary. Contributions were made to a fund for acerb subsisters. Spot painting competitions were organized for school kids in different cities/towns to an enthusiastic response. At our Silvassa works, employees volunteered for a blood contribution cantonment. Lifeline Foundation, working for main road deliverance and accident intervention, continues to be supported with financess for communicating. We have helped the local authorities with substructure development from clip to clip, for case, the Karkhadi panchayet with the building of panchayet office, the Dadra gm panchayet for the building of a route.
Directors
Shri S. Mohanchand Dadha and Shri Sailesh T. Desai retire by rotary motion and being eligible offer themselves for re-appointment. 31
The footings of assignment of Shri Sudhir V. Valia and Shri Sailesh T. Desai as Whole-Time Director will run out on 31st March, 2009. Both of these Directors have contributed good for all circular growing of the Company ‘s concern. Your Directors recommend the re-appointment of both managers for a farther period of 5 old ages.
Directors ‘ Responsibility Statement
Pursuant to the demand under Section 217 ( 2AA ) of the Companies Act, 1956, with regard to Directors ‘ Responsibility Statement, it is hereby confirmed:
( I ) that in the readying of the one-year histories for the fiscal twelvemonth ended 31st March, 2008, the applicable accounting criterions have been followed along with proper account associating to material goings ;
( two ) that the Directors have selected appropriate accounting policies and applied them systematically and made opinions and estimations that were sensible and prudent so as to give a true and just position of the province of personal businesss of the Company at the terminal of the fiscal twelvemonth and on the net income of the Company for the twelvemonth under reappraisal ;
( three ) that the Directors have taken proper and sufficient attention for the care of equal accounting records in conformity with the commissariats of the Companies Act, 1956 for safeguarding the assets of the Company and for forestalling and observing fraud and other abnormalities ; and,
( four ) that the Directors have prepared the one-year histories for the fiscal twelvemonth ended 31st March, 2008 on a ‘going concern ‘ footing.
